|
1
|
Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial.
|
Lancet
|
2012
|
3.12
|
|
2
|
Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention.
|
Circulation
|
2012
|
2.32
|
|
3
|
Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial.
|
Lancet
|
2011
|
2.10
|
|
4
|
Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis.
|
Eur Heart J
|
2008
|
2.01
|
|
5
|
Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study.
|
J Am Coll Cardiol
|
2010
|
1.93
|
|
6
|
Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial.
|
Eur Heart J
|
2009
|
1.81
|
|
7
|
Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
|
J Am Coll Cardiol
|
2009
|
1.73
|
|
8
|
Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin.
|
Am Heart J
|
2011
|
1.70
|
|
9
|
Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial.
|
Circulation
|
2009
|
1.69
|
|
10
|
Prognostic value of uric acid in patients with acute coronary syndromes.
|
Am J Cardiol
|
2012
|
1.67
|
|
11
|
Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
|
J Am Coll Cardiol
|
2012
|
1.49
|
|
12
|
Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age.
|
Catheter Cardiovasc Interv
|
2013
|
1.40
|
|
13
|
Correlates of poor outcome among patients with bleeding after coronary interventions.
|
Coron Artery Dis
|
2014
|
1.39
|
|
14
|
Patterns of presentation and outcomes of patients with acute coronary syndromes.
|
Cardiology
|
2009
|
1.39
|
|
15
|
[Treatment of Paclitaxel-eluting stent restenosis with sirolimus-eluting stent implantation: angiographic and clinical outcomes].
|
Rev Esp Cardiol
|
2008
|
1.38
|
|
16
|
2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents.
|
J Am Coll Cardiol
|
2010
|
1.38
|
|
17
|
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
|
N Engl J Med
|
2008
|
1.37
|
|
18
|
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
|
Eur Heart J
|
2011
|
1.29
|
|
19
|
Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.
|
N Engl J Med
|
2011
|
1.20
|
|
20
|
Rationale and design of a randomised clinical trial comparing vascular closure device and manual compression to achieve haemostasis after diagnostic coronary angiography: the Instrumental Sealing of ARterial puncture site - CLOSURE device versus manual compression (ISAR-CLOSURE) trial.
|
EuroIntervention
|
2014
|
1.16
|
|
21
|
Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non st-segment elevation myocardial infarction.
|
J Interv Cardiol
|
2013
|
1.10
|
|
22
|
Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes.
|
EuroIntervention
|
2014
|
1.10
|
|
23
|
A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
|
Eur Heart J
|
2009
|
1.08
|
|
24
|
Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial.
|
J Am Coll Cardiol
|
2011
|
1.07
|
|
25
|
Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients.
|
Catheter Cardiovasc Interv
|
2011
|
1.07
|
|
26
|
Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial.
|
Circ Cardiovasc Interv
|
2010
|
1.04
|
|
27
|
Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses.
|
Int J Cardiol
|
2012
|
1.01
|
|
28
|
Arylsulfatase G, a novel lysosomal sulfatase.
|
J Biol Chem
|
2008
|
0.98
|
|
29
|
Prognostic value of access and non-access sites bleeding after percutaneous coronary intervention.
|
Circ Cardiovasc Interv
|
2013
|
0.96
|
|
30
|
Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial.
|
Circulation
|
2011
|
0.95
|
|
31
|
Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window.
|
J Am Coll Cardiol
|
2010
|
0.95
|
|
32
|
PCSK6 VNTR Polymorphism Is Associated with Degree of Handedness but Not Direction of Handedness.
|
PLoS One
|
2013
|
0.94
|
|
33
|
Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials.
|
Thromb Haemost
|
2007
|
0.91
|
|
34
|
'Selective' reel syndrome?
|
Europace
|
2010
|
0.91
|
|
35
|
Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention.
|
Eur Heart J
|
2009
|
0.91
|
|
36
|
Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study.
|
Am Heart J
|
2009
|
0.90
|
|
37
|
Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials.
|
Clin Res Cardiol
|
2010
|
0.90
|
|
38
|
Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease.
|
J Am Coll Cardiol
|
2013
|
0.89
|
|
39
|
High-sensitivity troponin T level and angiographic severity of coronary artery disease.
|
Am J Cardiol
|
2011
|
0.89
|
|
40
|
Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention.
|
Circ Cardiovasc Interv
|
2009
|
0.88
|
|
41
|
A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment.
|
J Am Coll Cardiol
|
2010
|
0.88
|
|
42
|
Prognostic significance of epicardial blood flow before and after percutaneous coronary intervention in patients with acute coronary syndromes.
|
J Am Coll Cardiol
|
2008
|
0.85
|
|
43
|
Peak cardiac troponin-T level, scintigraphic myocardial infarct size and one-year prognosis in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.
|
Am J Cardiol
|
2010
|
0.85
|
|
44
|
Weight of the bleeding impact on early and late mortality after percutaneous coronary intervention.
|
J Thromb Thrombolysis
|
2015
|
0.84
|
|
45
|
Comparative efficacy of 2 zotarolimus-eluting stent generations: resolute versus endeavor stents in patients with coronary artery disease.
|
Am Heart J
|
2012
|
0.84
|
|
46
|
Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease.
|
Clin Res Cardiol
|
2013
|
0.83
|
|
47
|
Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment.
|
Clin Res Cardiol
|
2007
|
0.83
|
|
48
|
No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting.
|
Circ Cardiovasc Interv
|
2012
|
0.82
|
|
49
|
Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention.
|
Heart Vessels
|
2010
|
0.81
|
|
50
|
Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
|
Catheter Cardiovasc Interv
|
2013
|
0.80
|
|
51
|
Effects of G-CSF on systemic inflammation, coagulation and platelet activation in patients with acute myocardial infarction.
|
Thromb Res
|
2010
|
0.80
|
|
52
|
Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
|
Circ Cardiovasc Interv
|
2012
|
0.79
|
|
53
|
Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial.
|
EuroIntervention
|
2016
|
0.79
|
|
54
|
Total leucocyte count, but not C-reactive protein, predicts 1-year mortality in patients with acute coronary syndromes treated with percutaneous coronary intervention.
|
Clin Sci (Lond)
|
2009
|
0.79
|
|
55
|
Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel.
|
Eur Heart J
|
2010
|
0.78
|
|
56
|
Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality.
|
Am J Cardiol
|
2009
|
0.78
|
|
57
|
Predictors of antiplatelet response to prasugrel during maintenance treatment.
|
Platelets
|
2014
|
0.78
|
|
58
|
Prognostic value of minimal blood flow restoration in patients with acute myocardial infarction after reperfusion therapy.
|
Clin Res Cardiol
|
2009
|
0.78
|
|
59
|
High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring.
|
Platelets
|
2012
|
0.77
|
|
60
|
Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
|
Cardiology
|
2008
|
0.77
|
|
61
|
Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.
|
Thromb Haemost
|
2010
|
0.77
|
|
62
|
Prognostic value of kidney function in patients with ST-elevation and non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention.
|
Am J Kidney Dis
|
2009
|
0.77
|
|
63
|
Serum potassium levels on admission and infarct size in patients with acute myocardial infarction.
|
Clin Chim Acta
|
2009
|
0.77
|
|
64
|
Sensitive troponin and N-terminal probrain natriuretic peptide in stable angina.
|
Eur J Clin Invest
|
2011
|
0.77
|
|
65
|
Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis.
|
JACC Cardiovasc Interv
|
2009
|
0.76
|
|
66
|
Sex-related effectiveness of bivalirudin versus abciximab and heparin in non-ST-segment elevation myocardial infarction.
|
Am Heart J
|
2013
|
0.76
|
|
67
|
Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting.
|
Thromb Haemost
|
2013
|
0.76
|
|
68
|
Comparative in vitro degradation of the human hemorphin LVV-H7 in mammalian plasma analysed by capillary zone electrophoresis and mass spectrometry.
|
Biopharm Drug Dispos
|
2007
|
0.76
|
|
69
|
Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial.
|
Clin Res Cardiol
|
2011
|
0.76
|
|
70
|
Characterization of patients with bleeding complications who are at increased risk of death after percutaneous coronary intervention.
|
Heart Vessels
|
2010
|
0.75
|
|
71
|
Time-resolved fluorometric assay for the detection of endostatin in chromatographically separated extracts of natural peptides.
|
J Immunol Methods
|
2002
|
0.75
|
|
72
|
Reply: Aspirin Treatment and Outcomes After Percutaneous Coronary Intervention: Results of the ISAR-ASPI Registry.
|
J Am Coll Cardiol
|
2015
|
0.75
|
|
73
|
Will we ever know the optimal duration of dual antiplatelet therapy after drug-eluting stent implantation?
|
JACC Cardiovasc Interv
|
2011
|
0.75
|
|
74
|
Individualization of dual antiplatelet therapy duration after drug-eluting stent implantation: paradigm and reality.
|
Eur Heart J
|
2013
|
0.75
|
|
75
|
Comparison of prognostic value of high-sensitivity and conventional troponin T in patients with non-ST-segment elevation acute coronary syndromes.
|
Clin Chim Acta
|
2011
|
0.75
|
|
76
|
Bleeding after percutaneous coronary intervention in women and men matched for age, body mass index, and type of antithrombotic therapy.
|
Am Heart J
|
2013
|
0.75
|
|
77
|
Validated multi-component CZE-UV procedure for the quantification of human hemorphin LVV-H7 in plasma stability studies.
|
Anal Bioanal Chem
|
2006
|
0.75
|
|
78
|
Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention.
|
EuroIntervention
|
2016
|
0.75
|
|
79
|
Phosphorus depletion in forest soils shapes bacterial communities towards phosphorus recycling systems.
|
Environ Microbiol
|
2016
|
0.75
|